Short Interest Worth Watching: Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) Could Burn Your Long Portfolio After More Shorts

November 25, 2016 - By Ruchi Gupta   ·   0 Comments

Short Interest Worth Watching: Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) Could Burn Your Long Portfolio After More Shorts

The stock of Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) registered an increase of 6.52% in short interest. BCRX’s total short interest was 8.55M shares in November as published by FINRA. Its up 6.52% from 8.03 million shares, reported previously. With 611,100 shares average volume, it will take short sellers 14 days to cover their BCRX’s short positions. The short interest to Biocryst Pharmaceuticals Incorporated’s float is 20.1%. About 114,603 shares traded hands. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 73.04% since April 22, 2016 and is uptrending. It has outperformed by 67.63% the S&P500.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $444.82 million. The Firm designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. It currently has negative earnings. The Firm focuses on the treatment of rare diseases.

Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.21, from 0.79 in 2016Q1. The ratio is positive, as 17 funds sold all BioCryst Pharmaceuticals, Inc. shares owned while 31 reduced positions. 10 funds bought stakes while 28 increased positions. They now own 45.48 million shares or 10.25% less from 50.68 million shares in 2016Q1.
Comerica Bancorp, a Michigan-based fund reported 13,553 shares. Morgan Stanley accumulated 16,794 shares or 0% of the stock. Northeast Fin Consultants has invested 0.03% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Pnc Financial Services Grp accumulated 301 shares or 0% of the stock. Metropolitan Life Insurance New York last reported 63,516 shares in the company. Blackrock Group last reported 0% of its portfolio in the stock. Proshare Advsrs Limited Liability Co has 63,843 shares for 0% of their US portfolio. Creative Planning last reported 0% of its portfolio in the stock. Vhcp Ltd Llc accumulated 2.96% or 1.01M shares. Moreover, Comml Bank Of New York Mellon has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 306,563 shares. Retail Bank Of Montreal Can holds 0% or 1,000 shares in its portfolio. Oakworth Cap holds 150 shares or 0% of its portfolio. Tower Capital Lc (Trc), a New York-based fund reported 2,417 shares. Ra Capital Mngmt Llc holds 2.99 million shares or 1.18% of its portfolio. New York State Common Retirement Fund accumulated 0% or 69,300 shares.

Insider Transactions: Since August 9, 2016, the stock had 0 buys, and 5 sales for $20.50 million net activity. STAAB THOMAS R II sold 5,864 shares worth $30,388. BAKER BROS. ADVISORS LP sold $20.25 million worth of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Friday, August 12. $121,800 worth of shares were sold by Babu Yarlagadda S on Thursday, August 25. 8,357 shares were sold by Barnes Alane P, worth $35,684 on Wednesday, September 14.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Out of 8 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. BioCryst Pharmaceuticals has been the topic of 18 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was maintained by Jefferies on Friday, August 5 with “Hold”. PiperJaffray upgraded the shares of BCRX in a report on Friday, August 12 to “Overweight” rating. As per Tuesday, February 9, the company rating was maintained by FBR Capital. JP Morgan downgraded the stock to “Neutral” rating in Tuesday, February 9 report. On Wednesday, November 11 the stock rating was downgraded by Bank of America to “Underperform”. Needham downgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday, February 9 to “Hold” rating. The firm has “Buy” rating given on Tuesday, February 9 by Rodman & Renshaw. The company was downgraded on Thursday, August 4 by JMP Securities. As per Tuesday, February 9, the company rating was downgraded by Jefferies. The rating was upgraded by Zacks to “Sell” on Friday, August 7.

BCRX Company Profile

BioCryst Pharmaceuticals, Inc. (BioCryst), incorporated on November 15, 1991, is a biotechnology company. The Firm designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Firm focuses on the treatment of rare diseases. The Firm uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine.

Another recent and important BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news was published by Fool.com which published an article titled: “Here’s the Buzz Behind BioCryst Pharmaceuticals, Inc.’s 27% Gain in July” on August 11, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>